Regenerative medicine was identified as one of the top priorities for the US government in a report from the Subcommittee for Advanced Manufacturing of the National Science and Technology Council that advises the US President. The report acknowledged that cell-based medicine holds great potential to address critical medical issues related to cells, tissues, and organs particularly in … Read more
Last month in a rare bipartisan move, a new bill was introduced in the Congress to provide conditional approval to regenerative medicine products intended primarily to affect how FDA regulates the Human Cell, Tissue or cellular or tissue-based Products (HCT/Ps). The proposed bill, called the “Reliable and Effective Growth for Regenerative Health Options that Improve Wellness”, or … Read more
Genetic tests indicating risk of diseases based on genetic markers have gained in popularity and consumer acceptance over the last decade although regulators have frequently questioned the accuracy and clinical benefit of such tests. Genetic tests on otherwise healthy individuals to look for genetic markers and predicting the likelihood of getting a given disease are … Read more
March 2016 will likely be known for a myriad of actions taken by the US government to deal with drug overdose caused by prescription painkillers. First CDC released a new guideline for doctors who prescribe painkillers, followed by two new guidance documents by FDA, one adding a new black-box warning on all opioid painkillers, and … Read more
The breakthrough therapy designation (BTD) has been lauded as one of the most innovative of regulatory pathways as it modifies the conventional drug development, review and approval processes to speed up availability of new drugs to the patients. Since its implementation in 2012, more than 100 drugs have obtained this designation and already 39 new drugs have … Read more
FDA and CDC took several major steps this month to address abuse of prescription opiates. Opiate abuse is a major healthcare issue and has been termed a “crisis” and an “epidemic”. A detailed action plan was announced by FDA last month, one of the first major actions by the new FDA Commissioner. Abuse or Overdose accounts for about … Read more
Since the 2013 DOJ ruling against the Indian generic manufacturer, Ranbaxy, Indian manufacturers have been constantly in the news for all the wrong reasons. Although India is home to one of the World’s largest generic drug and API manufacturing industry with about 700 FDA-approved manufacturing facilities, the general impression is that Indian regulations are lax, and … Read more
The cardinal rule of raw material vendor management is to verify that vendor’s specification and documents related to the raw material being sourced. Errors in the quality of raw material could compromise the quality of the final product. In pharmaceutical GMP, raw material risk management is one of the core competencies. Not so in other … Read more
Social media holds a great promise as a recruitment tool for clinical trials. One can argue that sponsors can create awareness for a given trial and get more potential subjects contact sites by using social media. The most common social media portal used in clinical trial recruitment is Facebook, followed by clinicaltrials.gov and advertisement on patient specific web-sites. … Read more
The Breakthrough Therapy designation is perhaps one the strongest incentives available to developers of innovative therapies in the US. Since implementation of the Breakthrough designation in 2012, FDA has designated about 110 products and approved 30 new products in this category. Now European Medicines Agency (EMA) has created its own version similar to the US regulatory pathway, called … Read more
